TABLE 1.
The T-cell repertoire in MV-infected patients and vaccinees
| Sample source | HLA A and B type | Sample timea | V beta (BV) gene segment usage among CD8+ T lymphocytes
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BV1 | BV2 | BV3 | BV5S2/S3 | BV6S7 | BV7S1 | BV8 | BV9 | BV12 | BV13S1 | BV13S2 | BV17 | BV20 | BV21S3 | BV23 | |||
| Vaccinee | |||||||||||||||||
| CBL108 | NDe | 1st (2) | 2.36 | 3.55 | 2.08 | 3.80 | 0.51 | 7.48b | 1.54 | 0.50 | 0.63 | 1.37 | 0.97 | 21.76 | 10.53 | 0.74 | 15.53 |
| 2nd (42) | 3.93 | 3.52 | 3.85 | 3.56 | 0.86 | 7.98 | 2.21 | 0.51 | 0.64 | 2.14 | 1.07 | 9.60 | 8.39 | 1.63 | 12.34 | ||
| CBL121 | ND | 1st (6) | 3.39 | 2.34 | 0.49 | 4.18 | 0.50 | 1.00 | 2.70 | 7.81 | 0.99 | 2.16 | 2.68 | 31.13 | 1.08 | 0.33 | 1.33 |
| 2nd (32) | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 30.80 | ND | ND | ND | ||
| CBL134 (twin 1)c | ND | 1st (4) | 2.71 | 4.65 | 1.15 | 6.13 | 3.30 | 3.95 | 2.66 | 1.34 | 1.43 | 2.50 | 1.11 | 3.29 | 2.71 | 2.51 | 0.98 |
| CBL134 (twin 2)c | ND | 1st (4) | 5.90 | 5.65 | 0.93 | 3.85 | 2.91 | 1.43 | 5.72 | 1.30 | 2.15 | 4.32 | 0.96 | 4.97 | 2.57 | 1.92 | 0.81 |
| Patient | |||||||||||||||||
| M34 | ND | A | 12.16 | 4.62 | 0.27 | 1.00 | 0.70 | 3.20 | 9.15 | 1.35 | 3.80 | 2.63 | 0.41 | 4.49 | 0.36 | 1.12 | 0.86 |
| M35 | A2,3; B12,17 | A | 4.40 | 4.06 | 0.66 | 7.51 | 1.90 | 3.35 | 3.01 | 4.64 | 2.50 | 2.81 | 2.40 | 3.53 | 3.95 | 3.21 | 0.82 |
| M36 | A19,28; B22,41 | A | 2.15 | 3.49 | 0.00 | 7.38 | 0.89 | 3.70 | 0.00 | 0.00 | 3.61 | 3.45 | 0.00 | 1.49 | 1.03 | 0.00 | 0.78 |
| M37 | A9,28; B12,53 | A | 1.26 | 0.66 | 1.98 | 1.46 | 0.40 | 1.85 | 3.64 | 1.29 | 2.12 | 4.25 | 0.78 | 2.67 | 0.36 | 6.25 | 4.07 |
| F (18) | 4.36 | 5.09 | 1.59 | 2.63 | 1.89 | 1.49 | 4.29 | 0.59 | 1.10 | 6.04 | 2.09 | 4.21 | 1.03 | 4.60 | 1.89 | ||
| M39 | A2,28; B5,35 | A | 1.57 | 7.72 | 6.81 | 2.89 | 3.00 | 2.50 | 1.17 | 0.45 | 0.69 | 1.80 | 8.01 | 1.02 | 0.70 | 1.78 | 21.30 |
| F (24) | 5.54 | 10.37 | 3.10 | 2.44 | 2.72 | 0.86 | 3.34 | 0.48 | 1.85 | 2.73 | 4.58 | 2.42 | 0.83 | 1.20 | 12.38 | ||
| M40 | A19; B5,35 | A | 1.39 | 2.45 | 10.42 | 2.61 | 1.14 | 3.53 | 3.67 | 0.67 | 1.36 | 8.08 | 0.99 | 3.79 | 0.37 | 2.01 | 0.58 |
| M41 | A28; B15 | A | 3.79 | 3.23 | ND | 3.56 | 0.27 | 2.91 | 3.22 | 0.44 | 0.24 | 2.52 | 1.67 | 6.07 | 2.01 | 2.83 | 0.89 |
| M42 | A19,28; B5,35 | A | 5.00 | 3.58 | 2.41 | 5.94 | 0.83 | 0.59 | 16.04 | 0.18 | 1.28 | 3.23 | 0.57 | 1.98 | 4.55 | 2.00 | 0.32 |
| F (20) | ND | ND | ND | ND | ND | ND | 4.60 | ND | ND | ND | ND | ND | ND | ND | ND | ||
| M43 | A1,9; B16 | A | 8.24 | 11.45 | 0.15 | 2.52 | 2.20 | 10.07 | 4.01 | 2.27 | 1.03 | 2.05 | 2.21 | 2.60 | 1.67 | 2.05 | 0.52 |
| F (16) | ND | ND | ND | ND | ND | 5.60 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ||
| M44 | A1,10; B8,49 | A | 6.54 | 2.58 | 0.85 | 0.62 | 1.20 | 1.48 | 3.43 | 1.69 | 7.22 | 2.25 | 4.09 | 3.03 | 0.78 | 2.01 | 2.92 |
| M45 | A2,3; B7 | A | 2.17 | 3.66 | 1.14 | 2.35 | 1.08 | 2.70 | 2.15 | 0.00 | 0.00 | 1.32 | 5.10 | 3.57 | 4.17 | 1.06 | 4.26 |
| F (23) | 5.16 | 3.65 | 0.89 | 3.89 | 2.11 | 1.22 | 4.58 | 0.31 | 1.25 | 3.40 | 2.65 | 3.09 | 1.52 | 1.05 | 1.66 | ||
| M47 | A30,32; B35,53 | A | 2.38 | 5.62 | 8.60 | 6.01 | 1.57 | 0.45 | 13.51 | 1.58 | 1.68 | 2.07 | 1.45 | 4.83 | 1.16 | 0.82 | 0.61 |
| F (8) | 3.58 | 3.87 | 3.95 | 6.70 | 1.99 | 2.31 | 7.62 | ND | ND | ND | ND | ND | 1.42 | 1.99 | 0.56 | ||
| M49 | A19; B35,22 | A | 10.36 | 16.92 | 8.02 | 3.54 | 0.27 | 1.44 | 2.73 | 0.48 | 6.71 | 2.76 | 5.29 | 4.96 | 1.35 | 1.49 | 0.42 |
| F (15) | 7.57 | 10.19 | 1.58 | 4.41 | 2.16 | 5.22 | 3.65 | 0.99 | 3.83 | 2.19 | 2.82 | 4.43 | 1.88 | 3.33 | 1.46 | ||
| M51 | A19; B14,35 | A | 0.98 | 2.02 | 1.61 | 4.71 | 0.23 | 0.64 | 1.19 | 0.28 | 12.32 | 0.69 | 0.25 | 0.49 | 17.71 | 0.20 | 11.56 |
| M53 | A26,19; B8 | A | 3.39 | 5.77 | 0.63 | 3.17 | 0.55 | 6.11 | 6.87 | 1.13 | 1.56 | 4.99 | 1.69 | 5.52 | 4.17 | 1.93 | 1.40 |
| F (17) | 2.39 | 6.23 | 1.36 | 4.76 | 1.38 | 3.12 | 4.73 | 1.31 | 1.51 | 3.57 | 0.85 | 7.27 | 3.29 | 1.11 | 1.05 | ||
| M111 | A2,33; B15,50 | A | 1.92 | 4.09 | 1.22 | 2.08 | 0.55 | 0.72 | 4.34 | 0.07 | 1.24 | 7.80 | 0.65 | 23.05 | 12.34 | 7.00 | 5.68 |
| M152 | A31,68; B35,53 | A | 4.21 | 5.32 | 6.39 | 4.39 | 4.34 | 3.96 | 3.40 | 3.27 | 0.95 | 9.28 | 0.65 | 3.90 | 3.03 | 3.15 | 3.74 |
| M342 | A2,23; B7,53 | A | 2.73 | 4.53 | 5.54 | 2.75 | 1.68 | 3.96 | 3.02 | 1.95 | 1.33 | 8.06 | 1.62 | 4.57 | 2.64 | 2.49 | 10.89 |
| M132 | A | 7.17 | 4.67 | 3.67 | 3.70 | 1.18 | 2.67 | 5.84 | 0.44 | 1.81 | 0.81 | 0.96 | 5.25 | 2.31 | 1.24 | 0.55 | |
| 10 Gambian controls | |||||||||||||||||
| Mean | 3.73 | 4.69 | 2.20 | 3.55 | 2.11 | 1.77 | 4.34 | 0.74 | 1.51 | 3.35 | 1.99 | 3.80 | 3.01 | 1.69 | 1.03 | ||
| Standard deviation | 1.22 | 2.13 | 1.73 | 2.67 | 1.78 | 0.81 | 2.29 | 0.47 | 0.54 | 0.96 | 1.44 | 1.72 | 2.08 | 0.97 | 0.50 | ||
| Cutoff pointd | 7.40 | 11.06 | 7.38 | 11.57 | 7.45 | 4.20 | 11.22 | 2.15 | 3.13 | 6.22 | 6.31 | 8.96 | 9.24 | 4.60 | 2.54 | ||
| 4 Caucasian controls | |||||||||||||||||
| Mean | 6.46 | 4.62 | 3.75 | 3.88 | 2.33 | 2.04 | 4.51 | 0.89 | 1.59 | 3.54 | 3.59 | 3.63 | 2.42 | 1.94 | 1.53 | ||
| Standard deviation | 3.48 | 1.71 | 0.90 | 0.86 | 1.12 | 1.26 | 1.29 | 0.35 | 0.63 | 1.08 | 1.98 | 1.70 | 0.97 | 0.36 | 0.75 | ||
| Cutoff pointd | 16.90 | 9.75 | 6.45 | 6.46 | 5.69 | 5.82 | 8.38 | 1.94 | 3.48 | 6.78 | 9.53 | 8.73 | 5.33 | 3.02 | 3.78 | ||
a
1st, 2nd, A, and F represent first, second, acute, and follow-up samples, respectively. The number in parentheses indicates weeks after vaccination or infection.
b
Percentage of a particular TCR Vβ shown in bold was considered to be expanded.
c
These children are twins.
d
The cutoff point for a particular TCR Vβ family was calculated as the mean plus 3 standard deviations among controls (10 Gambian children recovering from malaria infection or 4 healthy Caucasian controls).
e
ND, not done.